Form 4: Biohaven Director John W. Childs Acquires 29,000 Shares

Biohaven director John W. Childs purchased 29,000 common shares at a weighted average price of $35.9446 on December 30, 2024.

Summary

• John W. Childs, a director at Biohaven Ltd., acquired 29,000 common shares on December 30, 2024.
• The shares were purchased at a weighted average price of $35.9446.
• The transactions occurred at prices ranging from $35.57 to $36.38.
• Following the transaction, Mr. Childs beneficially owns 2,368,741 shares indirectly through the John W Childs 2013 Revocable Trust.
• Mr. Childs also indirectly owns 4,096,512 shares through the 2021 B-H Charitable Remainder Trust, 21,052 shares through the 2007 Charitable Remainder Trust, and 24,391 shares through the 1994 Charitable Remainder Trust.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction, which is neither particularly positive nor negative. It indicates confidence from a director but is not a major event.

Positives

• The purchase of shares by a director can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is within the normal range of such activities.
• Similar filings are regularly made by directors and officers of companies like Pfizer, AbbVie, and Amgen, reflecting their personal investment decisions.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment, indicating confidence from a company director.

Key Dates

Keywords

Biohaven, John W. Childs, share purchase, director, insider trading, common stock, beneficial ownership